7-氟-4,4-二甲基-1,2,3,4-四氢-喹啉 | 1187933-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氟-4,4-二甲基-1,2,3,4-四氢-喹啉
• 英文名称: 7-Fluoro-4,4-dimethyl-1,2,3,4-tetrahydroquinoline
• 英文别名: 7-fluoro-4,4-dimethyl-2,3-dihydro-1H-quinoline
• CAS: 1187933-43-2
• 化学式: C₁₁H₁₄FN
• 分子量: 179.23
• InChiKey: KTAVEICIDOECMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
  申请人：AbbVie Inc.

  公开号：US20140080816A1

  公开（公告）日：2014-03-20

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.

  本发明涉及三环喹啉和喹噁啉衍生物，以及含有这些化合物的药物组合物，它们的用途为5-HT2C受体的调节剂，特别是激动剂或部分激动剂，用于制备用于预防或治疗对5-HT2C受体调节有反应的病症和疾病的药物，以及用于预防或治疗对5-HT2C受体调节有反应的病症和疾病的方法。
• Tricyclic quinoline and quinoxaline derivatives
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US10118926B2

  公开（公告）日：2018-11-06

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

  本发明涉及三环喹啉和喹喔啉衍生物，涉及含有此类化合物的药物组合物，涉及它们作为 5-HT2C 受体调节剂（尤其是激动剂或部分激动剂）的用途，涉及它们用于制备预防或治疗对 5-HT2C 受体调节有反应的病症和紊乱的药物，还涉及一种预防或治疗对 5-HT2C 受体调节有反应的病症和紊乱的方法。
• US8487099B2
  申请人：——

  公开号：US8487099B2

  公开（公告）日：2013-07-16
• [EN] TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES<br/>[FR] DÉRIVÉS TRICYCLIQUES DE QUINOLINE ET DE QUINOXALINE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014041131A1

  公开（公告）日：2014-03-20

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.